Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

Acid sphingomyelinase deficiency protects from cisplatin-induced gastrointestinal damage

Oncogene volume 27, pages 6590–6595 (2008)Cite this article

Abstract

Cisplatin is one of the most effectively used chemotherapeutic agents for cancer treatment. However, in humans, important cytotoxic side effects are observed including dose-limiting renal damage and profound gastrointestinal symptomatology. The toxic responses to cisplatin in mice are similar to those in human patients. Here, we evaluated whether the acid sphingomyelinase (Asm) mediates at least some of the toxic in vivo effects of cisplatin. To this end, we determined the toxic effects of a single intraperitoneal dose of cisplatin (27 mg/kg) in wild type (Asm+/+) and Asm-deficient mice (Asm−/−). Tissue injury and apoptosis were determined histologically on hematoxylin–eosin and TUNEL (terminal deoxynucleotidyl transferase (TdT)-mediated nick end labeling) stainings 3, 12, 36 and 72 h after treatment. Our results revealed severe toxicity of cisplatin in Asm+/+ mice with increased numbers of apoptotic cells in the thymus and small intestine. In marked contrast, Asm−/− mice were resistant to cisplatin and no apoptosis was observed in these organs after treatment. Moreover, cisplatin treatment primarily triggered apoptosis of endothelial cells in microvessels of intestine and thymus, an effect that was absent in mice lacking Asm. The data thus suggest that at least some toxic effects of cisplatin are mediated by the Asm in vivo resulting in early death of endothelial cells and consecutive organ damage.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Allan SG, Smyth JF . (1986). Small intestinal mucosal toxicity of cis-platinum—comparison of toxicity with platinum analogues and dexamethasone. Br J Cancer 53: 355–360.

    Article  CAS  Google Scholar 

  • Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Muller S et al. (2004). Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 104: 1166–1173.

    Article  CAS  Google Scholar 

  • Grunicke H, Hofmann J . (1992). Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level. Pharmacol Ther 55: 1–30.

    Article  CAS  Google Scholar 

  • Gulbins E, Grassme H . (2002). Ceramide and cell death receptor clustering. Biochim Biophys Acta 1585: 139–145.

    Article  CAS  Google Scholar 

  • Gulbins E, Kolesnick R . (2003). Raft ceramide in molecular medicine. Oncogene 22: 7070–7077.

    Article  CAS  Google Scholar 

  • Harrison Jr SD . (1981). Toxicologic evaluation of cis-diamminedichloroplatinum II in B6D2F1 mice. Fundam Appl Toxicol 1: 382–385.

    Article  CAS  Google Scholar 

  • Horinouchi K, Erlich S, Perl DP, Ferlinz K, Bisgaier CL, Sandhoff K et al. (1995). Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease. Nat Genet 10: 288–293.

    Article  CAS  Google Scholar 

  • Huang C, Ma W, Ding M, Bowden GT, Dong Z . (1997). Direct evidence for an important role of sphingomyelinase in ultraviolet-induced activation of c-Jun N-terminal kinase. J Biol Chem 272: 27753–27757.

    Article  CAS  Google Scholar 

  • Lacour S, Hammann A, Grazide S, Lagadic-Gossmann D, Athias A, Sergent O et al. (2004). Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res 64: 3593–3598.

    Article  CAS  Google Scholar 

  • Loehrer PJ, Einhorn LH . (1984). Drugs five years later. Cisplatin. Ann Intern Med 100: 704–713.

    Article  CAS  Google Scholar 

  • Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A et al. (2000). Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 6: 1109–1114.

    Article  CAS  Google Scholar 

  • Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D et al. (2001). Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293: 293–297.

    Article  CAS  Google Scholar 

  • Pena LA, Fuks Z, Kolesnick RN . (2000). Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res 60: 321–327.

    CAS  Google Scholar 

  • Prestayko AW, Bradner WT, Huftalen JB, Rose WC, Schurig JE, Cleare MJ et al. (1979). Antileukemia (L1210) activity and toxicity of cis-dichlorodiammineplatinum(II) analogs. Cancer Treat Rep 63: 1503–1508.

    CAS  Google Scholar 

  • Rebillard A, Tekpli X, Meurette O, Sergent O, Le Moigne-Muller G, Vernhet L et al. (2007). Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells. Cancer Res 67: 7865–7874.

    Article  CAS  Google Scholar 

  • Sansom OJ, Clarke AR . (2002). The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice. Oncogene 21: 5934–5939.

    Article  CAS  Google Scholar 

  • Santana P, Pena LA, Haimovitz-Friedman A, Martin S, Green D, McLoughlin M et al. (1996). Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86: 189–199.

    Article  CAS  Google Scholar 

  • Tamaki T, Naomoto Y, Kimura S, Kawashima R, Shirakawa Y, Shigemitsu K et al. (2003). Apoptosis in normal tissues induced by anti-cancer drugs. J Int Med Res 31: 6–16.

    Article  CAS  Google Scholar 

  • Vasey PA, Jones NA, Jenkins S, Dive C, Brown R . (1996). Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 50: 1536–1540.

    CAS  Google Scholar 

Download references

Acknowledgements

We thank F Paris, M Le Vée and I Guénon. This study was supported by grants from the Ligue Nationale Contre le Cancer (the Côte d'Armor, Ille et Vilaine and Loire-Atlantique Committees), Rennes Métropole, the Région Bretagne and DFG-10-2238-Gu2.

Author information

Authors and Affiliations

  1. Inserm, UMR620, IFR 140 GFAS, Rennes, France

    A Rebillard, C Muller, O Meurette, E Jouan, L Vernhet, C Le Quément, D Lagadic-Gossmann & M T Dimanche-Boitrel

  2. UPRES EA SeRAIC, University of Rennes, Rennes, France

    A Rebillard, O Meurette, E Jouan, L Vernhet, C Le Quément, D Lagadic-Gossmann & M T Dimanche-Boitrel

  3. Department of Pathology, Hospital, Rennes University, Rennes, France

    N Rioux-Leclercq & P Bellaud

  4. CNRS/UMR6061, Rennes University, Rennes, France

    N Rioux-Leclercq & F Jouan

  5. Department of Molecular Biology, University of Duisburg-Essen, Essen, Germany

    A Carpinteiro, M Schenck & E Gulbins

Authors
  1. A Rebillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Rioux-Leclercq
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Muller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Bellaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Jouan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O Meurette
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Jouan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Vernhet
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Le Quément
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Carpinteiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Schenck
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D Lagadic-Gossmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E Gulbins
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M T Dimanche-Boitrel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M T Dimanche-Boitrel.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rebillard, A., Rioux-Leclercq, N., Muller, C. et al. Acid sphingomyelinase deficiency protects from cisplatin-induced gastrointestinal damage. Oncogene 27, 6590–6595 (2008). https://doi.org/10.1038/onc.2008.257

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2008.257

Keywords

This article is cited by

Search

Advanced search

Quick links